Lilly’s Ebglyss Delivers 4-Year Disease Control in Atopic Dermatitis

Long-term consistency is rare in eczema treatment. Eli Lilly and Company just shared new data showing that Ebglyss (lebrikizumab) can deliver durable skin clearance and itch relief for up to four years in patients with moderate-to-severe atopic dermatitis.

The data comes from an extension study presented at the American Academy of Dermatology Annual Meeting.

Why This Data Matters?

Most eczema therapies focus on:

• Short-term symptom control
• Frequent topical applications
• Managing flare cycles

But patients want: Stable, long-term disease control. This study suggests Ebglyss might deliver exactly that.

The Study: ADlong Extension Trial

The findings come from:

• ADlong study
• Open-label extension
• Patients followed for up to 4 years
• Once-monthly maintenance dosing (250 mg Q4W)

Participants:

• Moderate-to-severe atopic dermatitis
• Previously enrolled in earlier Phase III trials

Key Results: Durable Outcomes

1. High Rates of Skin Clearance

• Majority achieved near-complete skin clearance
• Sustained over multiple years

2. Significant Itch Relief

• Persistent reduction in chronic itch
• One of the most debilitating symptoms

3. Minimal Reliance on Topicals

• 77% on Ebglyss monotherapy
• 80% maintained results without topical steroids

4. Monthly Dosing Works

• 80% achieved outcomes with once-monthly injections

Flare Control: A Key Differentiator

A post-hoc analysis showed:

• <1 flare per patient per year

That’s a major shift from:

• Frequent, unpredictable flare cycles
• Daily topical burden

Safety Profile

• Consistent with earlier studies
• No new safety signals

Reported Adverse Events:

• Conjunctivitis → 6.9%
• Injection-site reactions → 0.6%

Most events were:

• Mild to moderate
• Did not lead to discontinuation

Mechanism: Targeting IL-13

Ebglyss is a monoclonal antibody targeting:

→ Interleukin-13 (IL-13)

Why IL-13 Matters:

• Central driver of type 2 inflammation
• Leads to:
  • Skin barrier dysfunction
  • Chronic itch
  • Skin thickening
  • Infection risk

What Ebglyss Does:

• Blocks IL-13 signalling
• Interrupts the inflammatory loop

Treats root cause, not just symptoms

Dosing Simplicity

Treatment Regimen:

• Initial phase:
  • 500 mg at Week 0 & 2
  • Then 250 mg every 2 weeks
• Maintenance:
  • 250 mg once monthly

→ Can be used with or without topical corticosteroids

Competitive Positioning

Ebglyss stands out on three fronts:

1. Long-Term Data

• Up to 4 years durability
• Few biologics have this depth

2. Monotherapy Potential

• Reduces reliance on topicals

3. Convenient Dosing

• Monthly maintenance vs more frequent biologics

Regulatory Footprint

Ebglyss is already approved in:

• United States (2024)
• Japan
• Canada
• European Union (2023)

The Bigger Strategy

Lilly is doubling down on immunology:

• Expanding biologics in dermatology
• Exploring next-gen modalities
• Investigating combinations (e.g., incretin + immunology)

Pipeline includes:

• IL-17 inhibitors
• Novel antibodies targeting inflammatory pathways

Final Take

Ebglyss isn’t just another eczema biologic. It’s making a stronger claim: Sustained disease control with minimal treatment burden

Three things stand out:

• Durability: up to 4 years
• Simplicity: monthly dosing
• Independence: less reliance on topicals

If these results hold in broader real-world use:

• Ebglyss could shift eczema treatment from flare management to long-term disease stability

That’s the real upgrade patients have been waiting for.